Axonics is a medical technology company that develops and commercializes products to treat urinary and fecal dysfunction, including: an implantable sacral neuromodulation (SNM) system to treat urinary urge incontinence and urinary urgency frequency, together referred to as overactive bladder, fecal incontinence, and non-obstructive urinary retention ; and a urethral bulking agent to treat female stress urinary incontinence. The implantable components of Co.'s rechargeable SNM system deliver mild electrical pulses to the targeted sacral nerve, most frequently the S3 nerve, in order to correct the dysfunction by restoring normal communication to and from the brain. The AXNX stock yearly return is shown above.
The yearly return on the AXNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AXNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|